Barely Significant
← all excerpts

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.

Arthritis Res Ther · 2020 · PMC7161150 · PMID 32293539

Europe PMCDOI
1
hedged sentence
0.0170
closest p · 0.3× alpha
0.0170
boldest claim

The sentences

borderline significantp = 0.017actually significant
PGA decreased from 1.2 [1–2.7] at adalimumab initiation to 0.5 [0.1–1.4] ( p = 0.017; borderline significant) at 12 months.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.